CONTEXT THERAPEUTICS INC (CNTX) Stock Price, Quote, News and Overview
NASDAQ:CNTX - Nasdaq - US21077P1084 - Common Stock - Currency: USD
CNTX Quote, Performance and Key Statistics
0.691
+0.01 (+1.8%)
The current stock price of CNTX is 0.691 USD. In the past month the price decreased by -26.78%. In the past year, price decreased by -65.45%.
CNTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 52.69 | 687.25B | ||
| JNJ | JOHNSON & JOHNSON | 15.24 | 368.56B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.49 | 302.74B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.57 | 222.75B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.73 | 216.03B | ||
| MRK | MERCK & CO. INC. | 9.88 | 193.71B | ||
| PFE | PFIZER INC | 7.18 | 130.67B | ||
| SNY | SANOFI-ADR | 13.78 | 129.50B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.4 | 95.65B | ||
| GSK | GSK PLC-SPON ADR | 6.99 | 77.98B | ||
| ZTS | ZOETIS INC | 26.82 | 72.01B | ||
| HLN | HALEON PLC-ADR | 22.65 | 50.05B |
Related stock screener links
About CNTX
Company Profile
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 12 full-time employees. The company went IPO on 2021-10-20. The company is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.
Company Info
CONTEXT THERAPEUTICS INC
2001 Market Street, Suite 3915 Unit #15
PHILADELPHIA PENNSYLVANIA US
Employees: 12
Phone: 12672257416
CONTEXT THERAPEUTICS INC / CNTX FAQ
What is the stock price of CONTEXT THERAPEUTICS INC today?
The current stock price of CNTX is 0.691 USD. The price increased by 1.8% in the last trading session.
What is the ticker symbol for CONTEXT THERAPEUTICS INC stock?
The exchange symbol of CONTEXT THERAPEUTICS INC is CNTX and it is listed on the Nasdaq exchange.
On which exchange is CNTX stock listed?
CNTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CONTEXT THERAPEUTICS INC stock?
12 analysts have analysed CNTX and the average price target is 6.38 USD. This implies a price increase of 822.58% is expected in the next year compared to the current price of 0.691. Check the CONTEXT THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CONTEXT THERAPEUTICS INC worth?
CONTEXT THERAPEUTICS INC (CNTX) has a market capitalization of 61.98M USD. This makes CNTX a Micro Cap stock.
How many employees does CONTEXT THERAPEUTICS INC have?
CONTEXT THERAPEUTICS INC (CNTX) currently has 12 employees.
What are the support and resistance levels for CONTEXT THERAPEUTICS INC (CNTX) stock?
CONTEXT THERAPEUTICS INC (CNTX) has a support level at 0.67 and a resistance level at 0.72. Check the full technical report for a detailed analysis of CNTX support and resistance levels.
Should I buy CONTEXT THERAPEUTICS INC (CNTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CNTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CNTX, evaluating the profitability, health, valuation and growth aspects
- CONTEXT THERAPEUTICS INC (CNTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CONTEXT THERAPEUTICS INC (CNTX) Sales and EPS estimates to see what analysts future expectations are.
- CONTEXT THERAPEUTICS INC (CNTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CONTEXT THERAPEUTICS INC (CNTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- CONTEXT THERAPEUTICS INC (CNTX) Stock Chart to make your own analysis
- CONTEXT THERAPEUTICS INC (CNTX) Latest news and press-releases to stay up to date.
Does CONTEXT THERAPEUTICS INC (CNTX) stock pay dividends?
CNTX does not pay a dividend.
What is the Price/Earnings (PE) ratio of CONTEXT THERAPEUTICS INC (CNTX)?
CONTEXT THERAPEUTICS INC (CNTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.35).
What is the Short Interest ratio of CONTEXT THERAPEUTICS INC (CNTX) stock?
The outstanding short interest for CONTEXT THERAPEUTICS INC (CNTX) is 2.48% of its float. Check the ownership tab for more information on the CNTX short interest.
CNTX Technical Analysis
CNTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CNTX. No worries on liquidiy or solvency for CNTX as it has an excellent financial health rating, but there are worries on the profitability.
CNTX Financial Highlights
Over the last trailing twelve months CNTX reported a non-GAAP Earnings per Share(EPS) of -0.35. The EPS increased by 73.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.24% | ||
| ROE | -28.05% | ||
| Debt/Equity | 0 |
CNTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CNTX. The Buy consensus is the average rating of analysts ratings from 12 analysts.